|
|
VSA-2 |
|
Vaxjo ID |
207 |
|
Vaccine Adjuvant Name |
VSA-2 |
|
Adjuvant VO ID |
VO_0005325
|
|
Description |
A vaccine adjuvant that is synthesized by derivatizing a natural Momordica saponin in one step. VSA-2 is chemically stable. VSA-2 is much less toxic than QS-21. VSA-2 is more Th1-biased than QS-21. Momordica saponins are isolated from widely available and sustainable source |
|
Stage of Development |
Research |
|
Location Licensed |
US (U of Alabama:Birmingham) |
|
Host Species for Testing |
3 |
|
Components |
Momordica saponins |
|
Storage |
4C |
|
Preparation |
incorporating a terminal-functionalized side chain to the branched trisaccharide domain at the C3 position of Momordica saponin II (MS II) isolated from the seeds of perennial Momordica cochinchinensis Spreng |
|
Function |
innate immune activation |
| References |
(Wang, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=42]
Kim et al., 2022: Kim H, Bai D, Ghosh S, Franks ML, Wang X, Yan C, Liu Z, Zhang P, Michalek SM, Leavenworth JW, Wang P. Structure-Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine Adjuvants. Journal of medicinal chemistry. 2022; 65(21); 14589-14598. [PubMed: 36318612].
Wang et al., 2020: Wang P, Ding X, Kim H, Michalek SM, Zhang P. Structural Effect on Adjuvanticity of Saponins. Journal of medicinal chemistry. 2020; 63(6); 3290-3297. [PubMed: 32101001].
|
|
